34584-69-5

Basic information

• Product Name: 3,6-Dichloro-4,5-dimethylpyridazine
• Synonyms: 3,6-DICHLORO-4,5-DIMETHYLPYRIDAZINE;Pyridazine, 3,6-dichloro-4,5-diMethyl-
• CAS NO: 34584-69-5
• Molecular Formula: C₆H₆Cl₂N₂
• Molecular Weight: 177.03
• Mol File: 34584-69-5.mol

Chemical Properties

• Melting Point: 120-121 °C
• Boiling Point: 317.165 °C at 760 mmHg
• Flash Point: 174.99 °C
• Appearance: /
• Density: 1.338 g/cm³
• Vapor Pressure: 0.000728mmHg at 25°C
• Refractive Index: 1.545
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.29±0.10(Predicted)
• CAS DataBase Reference: 3,6-Dichloro-4,5-dimethylpyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6-Dichloro-4,5-dimethylpyridazine(34584-69-5)
• EPA Substance Registry System: 3,6-Dichloro-4,5-dimethylpyridazine(34584-69-5)

Safety Data

• Hazardous Substances Data: 34584-69-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3,6-Dichloro-4,5-dimethylpyridazine is used as a pharmaceutical intermediate for the synthesis of various drugs and medications. Its chemical structure allows for further functionalization and modification, making it a versatile building block in the development of new pharmaceutical compounds. 3,6-Dichloro-4,5-dimethylpyridazine's reactivity and stability contribute to its utility in creating a wide range of therapeutic agents.
As a pharmaceutical intermediate, 3,6-Dichloro-4,5-dimethylpyridazine plays a crucial role in the development of new drugs with potential applications in treating various medical conditions. Its unique structure and properties enable chemists to design and synthesize novel compounds with improved pharmacological profiles, including enhanced efficacy, selectivity, and safety profiles. This makes 3,6-Dichloro-4,5-dimethylpyridazine a valuable asset in the ongoing efforts to discover and develop innovative therapeutic solutions to address unmet medical needs.

InChI:InChI=1/C6H6Cl2N2/c1-3-4(2)6(8)10-9-5(3)7/h1-2H3

Upstream product

• 71-43-2 benzene 
• 766-39-2 2,3-Dimethylmaleic anhydride 
• 5754-17-6 6-hydroxy-4,5-dimethylpyridazin-3-one 
• 63751-07-5 1-amino-3,4-dimethyl-pyrrole-2,5-dione 
• 5754-17-6 4,5-dimethyl-1,2-dihydro-pyridazine-3,6-dione 

Downstream Products

• 1204978-32-4 3-chloro-4,5-dimethyl-6-((R)-3-methyl-piperazin-1-yl)-pyridazine 
• 1204978-49-3 3-Chloro-4,5-dimethyl-6-[(R)-3-methyl-4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyridazine 
• 1227064-32-5 N₁-benzyl-N₂-(6-chloro-4,5-dimethylpyridazin-3-yl)ethane-1,2-diamine 
• 1057682-54-8 1,4-dichloro-6-[4-methoxybenzyl]-6H-dihydro-5H-pyrrolo[3,4-d]pyridazine 
• 1057682-50-4 N-benzyl-1-(3,6-dichloro-5-methylpyridazin-4-yl)methanamine 

Relevant articles and documents

Pyridazine N-Oxides as Photoactivatable Surrogates for Reactive Oxygen Species

A method for the photoinduced evolution of atomic oxygen from pyridazine N-oxides was developed. This underexplored oxygen allotrope mediates arene C-H oxidation within complex, polyfunctional molecules. A water-soluble pyridazine N-oxide was also developed and shown to promote photoinduced DNA cleavage in aqueous solution. Taken together, these studies highlight the utility of pyridazine N-oxides as photoactivatable O(3P) precursors for applications in organic synthesis and chemical biology.

PYRIDAZINE DERIVATIVES AS HEDGEHOG PATHWAY INHIBITORS

This invention relates to novel compounds. The compounds of the invention are hedgehog pathway agonists. Specifically, the compounds of the invention are useful as Smoothened (SMO) agonists. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of the Hedgehog pathway and SMO, for example cancer.

HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS

This invention relates to novel compounds of formula (I). The compounds of the invention are hedgehog pathway antagonists. Specifically, the compounds of the invention are useful as Smoothened (SMO) inhibitors. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of the Hedgehog pathway and SMO, for example cancer.

TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS

The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The i

TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS

The invention relates to novel compounds of formula I where X, A?, Q1, Q2 Q3, R2, R3, R4, R5, R6, R7, R8 and R9 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated recepto

PIPERIDINYLAMINO-PYRIDAZINES AND THEIR USE AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS

The present invention relates to 6-(piperidin-4-ylamino)pyridazin-3-carbonitriles of formula (I) that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects.

NOVEL ALLYLTHIOPYRIDAZINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME

The, present invention relates to a novel allylthiopyridazine derivative represented by formula (I) which exhibits a superior effect for prevention and treatment or hepatic diseases induced by toxic substances and for protection of human tissues from radi

Allylthiopyridazine derivatives and process for preparing the same

The, present invention relates to a novel allylthiopyridazine derivative represented by formula (I) which exhibits a superior effect for prevention and treatment or hepatic diseases induced by toxic substances and for protection of human tissues from radi

Preparation of substituted pyridazines

A novel process is described for preparing substituted pyridazines, where a less substituted pyridazine is reacted with a carboxylic acid in the presence of a silver ion as catalyst, using peroxydisulfate ion. The reaction is run at a temperature from about 40° to 80° C. in an aqueous solvent system and mineral acid. The substituted pyridazines are useful as intermediates to herbicidal and fungicidal compounds.